Skip to content
value.today

Lux Biosciences Inc.

🇺🇸 Jersey City, New Jersey, USABiotechnologyFounded 2005
Total raised
$81 M
7 rounds on record
Latest round
$16 M
Feb 2012
First round on record
Jun 2009
Today
Private
No later event on record

Funding rounds

7 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Lux Biosciences Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2012$16 MNo. 7$10 to $50 million

Lux Biosciences Inc.: Raise no. 7, Feb 2012

Investors in this round

8 investors had bought by the notice of Mar 6, 2012: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$16 M of $17 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • A. Clarke Atwell · Executive Officer
  • Eddy Anglade · Executive Officer
  • Axel Clarke Bolte · Director
  • David Clarke Guyer · Director
  • David Clarke Schnell · Director
  • Dean Clarke Mitchell · Director
  • Lutz Clarke Giebel · Director
  • Paul Clarke Chaney · Director
  • Thomas Clarke Dyrberg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by George Eldridge, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 6, 2012. Read the notice at the SEC.

debt, optionsSEC
Dec 2011$4 MNo. 6$2 to $10 million

Lux Biosciences Inc.: Raise no. 6, Dec 2011

Investors in this round

10 investors had bought by the notice of Dec 12, 2011: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • A. Clarke Atwell · Executive Officer
  • Eddy Anglade · Executive Officer
  • Axel Clarke Bolte · Director
  • David Clarke Guyer · Director
  • David Clarke Schnell · Director
  • Dean Clarke Mitchell · Director
  • Lutz Clarke Giebel · Director
  • Paul Clarke Chaney · Director
  • Thomas Clarke Dyrberg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by George Eldridge, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 12, 2011. Read the notice at the SEC.

debt, optionsSEC
Jun 2011$6 MNo. 5$2 to $10 million

Lux Biosciences Inc.: Raise no. 5, Jun 2011

Investors in this round

10 investors had bought by the notice of Jul 14, 2011: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • A. Clarke Atwell · Executive Officer
  • Dean Clarke Mitchell · Executive Officer, Director
  • Eddy Anglade · Executive Officer
  • Axel Clarke Bolte · Director
  • David Clarke Guyer · Director
  • David Clarke Schnell · Director
  • Lutz Clarke Giebel · Director
  • Paul Clarke Chaney · Director
  • Thomas Clarke Dyrberg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by George Eldridge, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 14, 2011. Read the notice at the SEC.

debt, optionsSEC
Mar 2011$3 MNo. 4$2 to $10 million

Lux Biosciences Inc.: Raise no. 4, Mar 2011

Investors in this round

10 investors had bought by the notice of Mar 18, 2011: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $5 M offered; $2 M still to sell
Smallest investment taken
$6,916
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • A. Clarke Atwell · Executive Officer
  • Dean J Mitchell · Executive Officer, Director
  • Eddy Clarke Anglade · Executive Officer
  • George J Eldridge · Executive Officer
  • Axel Clarke Bolte · Director
  • David Clarke Guyer · Director
  • David G. Schnell · Director
  • Lutz Clarke Giebel · Director
  • Paul G. Chaney · Director
  • Thomas Clarke Dyrberg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by George Eldridge, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 18, 2011. Read the notice at the SEC.

debt, optionsSEC
Dec 2010$5 MNo. 3$2 to $10 million

Lux Biosciences Inc.: Raise no. 3, Dec 2010

Investors in this round

10 investors had bought by the notice of Dec 20, 2010: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
$11,526
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • A. Clarke Atwell · Executive Officer
  • Dean J Mitchell · Executive Officer, Director
  • Eddy Clarke Anglade · Executive Officer
  • George J Eldridge · Executive Officer
  • Axel Clarke Bolte · Director
  • David Clarke Guyer · Director
  • David G. Schnell · Director
  • Lutz Clarke Giebel · Director
  • Paul G. Chaney · Director
  • Thomas Clarke Dyrberg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by George Eldridge, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 20, 2010. Read the notice at the SEC.

debt, optionsSEC
Oct 2009$38 MNo. 2$10 to $50 million

Lux Biosciences Inc.: Raise no. 2, Oct 2009

Investors in this round

10 investors had bought by the notice of Oct 30, 2009: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$38 M of $50 M offered; $12 M still to sell
Smallest investment taken
$87,302
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • A. Clarke Atwell · Executive Officer
  • Brett Clarke Skolnik · Executive Officer
  • Eddy Clarke Anglade · Executive Officer
  • Ulrich M. Grau · Executive Officer, Director
  • Axel Clarke Bolte · Director
  • David Clarke Guyer · Director
  • David G. Schnell · Director
  • Lutz Clarke Giebel · Director
  • Paul G. Chaney · Director
  • Thomas Clarke Dyrberg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Brett Skolnik, Chief Financial Officer. Source: SEC Form D, newest notice filed Oct 30, 2009. Read the notice at the SEC.

equitySEC
Jun 2009$9 MNo. 1$2 to $10 million

Lux Biosciences Inc.: Raise no. 1, Jun 2009

Investors in this round

10 investors had bought by the notice of Jun 16, 2009: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $9 M offered
Smallest investment taken
$21,167
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • A. Clarke Atwell · Executive Officer
  • Brett Skolnik · Executive Officer
  • Eddy Anglade · Executive Officer
  • Ulrich M. Grau · Executive Officer, Director
  • Axel Bolte · Director
  • David Guyer · Director
  • David Schnell · Director
  • Lutz Giebel · Director
  • Paul G. Chaney · Director
  • Thomas Dyrberg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Brett Skolnik, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 16, 2009. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Lux Biosciences Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2012).

    SEC Form D · Mar 2012

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2012

That is all the official record says: Lux Biosciences Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Lux Biosciences Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 7 rounds above had up to 10 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Lux Biosciences Inc.
NameRoleNamed in
A. Clarke AtwellExecutive officerMar 2012
Eddy AngladeExecutive officerMar 2012
Dean Clarke MitchellExecutive officerJul 2011
Dean J MitchellExecutive officerMar 2011
Eddy Clarke AngladeExecutive officerMar 2011
George J EldridgeExecutive officerMar 2011
Brett Clarke SkolnikExecutive officerOct 2009
Ulrich M. GrauExecutive officerOct 2009
Brett SkolnikExecutive officerJun 2009
Axel Clarke BolteDirectorMar 2012
David Clarke GuyerDirectorMar 2012
David Clarke SchnellDirectorMar 2012
Dean Clarke MitchellDirectorMar 2012
Lutz Clarke GiebelDirectorMar 2012
Paul Clarke ChaneyDirectorMar 2012
Thomas Clarke DyrbergDirectorMar 2012
David G. SchnellDirectorMar 2011
Dean J MitchellDirectorMar 2011
Paul G. ChaneyDirectorMar 2011
Ulrich M. GrauDirectorOct 2009
Axel BolteDirectorJun 2009
David GuyerDirectorJun 2009
David SchnellDirectorJun 2009
Lutz GiebelDirectorJun 2009
Thomas DyrbergDirectorJun 2009